Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
2.05 p
0.00 p(0.00%)
At close: 4:00 PM EDT
2.05 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume400.24K
Average Volume (3M)1.23M
Market Cap
£8.71M
Enterprise Value12.21M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clear Focus On Blood-based Lung Cancer DiagnosticsCizzle's strategic focus on blood-based assays for early lung cancer targets a durable, high-value clinical need where screening and earlier detection produce long-term demand. A validated blood test can unlock clinical adoption, referral pathways and long-term commercial opportunities.
Low Reported Debt Reduces Near-term Default RiskWith negligible reported debt, the company faces lower immediate insolvency risk and limited interest burden, giving management more flexibility to pursue partnerships, grants or equity raises. This structural advantage lowers fixed financial obligations while development continues.
Defined Development And Validation Pathway Toward CommercializationA stated emphasis on development and validation provides a clear, durable roadmap to regulatory acceptance and payer/provider uptake. Meeting validation milestones can materially de-risk the science, enable partnerships or licensing, and form the basis for sustainable future revenue streams.
Bears Say
Negative Shareholders' Equity And Shrinking Asset BaseShareholders' equity turning negative and a collapsing asset base materially reduce financial flexibility and increase the urgency of external funding. This structural deterioration constrains balance-sheet capacity for investments, complicates partner or lender assessments and raises dilution risk for shareholders.
Consistent Operating Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flows indicate an ongoing funding gap that will require equity, grant or partnership financing. Structurally, sustained cash burn elevates execution risk, shortens runway for development milestones, and increases the probability of dilutive capital raises.
Pre-revenue Model With Persistent Operating LossesBeing pre-revenue with recurring operating losses leaves the company dependent on external capital until commercialization. This business model carries inherent execution and funding risk: delays in clinical validation or reimbursement could extend losses and further pressure the balance sheet.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £8.71M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 56 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.